Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Phase 1/2
74
about 1.8 years
18–55
1 site in CA
About this study
Researchers are testing whether clemastine fumarate, a drug, can help repair myelin damage in people with multiple sclerosis. The trial will use multi-parametric MRI and UTE MRI to see if clemastine fumarate has a protective or reparative effect on chronic lesions found in patients with relapsing-remitting MS.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Clemastine Fumarate
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Respiratory System Agent (Histamine H1 Receptor Antagonists)
oral (Oral Tablet)
Primary: Change from Baseline in Corpus Callosum Myelin Water Fraction at 3 Months, Change from Baseline in Corpus Callosum Myelin Water Fraction at 6 Months, Change from Baseline in Corpus Callosum T1 Relaxation Time at 3 Months, Change from Baseline in Corpus Callosum T1 Relaxation Time at 6 Months, Change from Baseline in Corpus Callosum UTE Fraction at 3 Months, Change from Baseline in Corpus Callosum UTE Fraction at 6 Months
Secondary: Change from Baseline in Clemastine Tolerability at 3 Months, Change from Baseline in Clemastine Tolerability at 6 Months, Change from Baseline in Corticospinal T1 Relaxation Time at 3 Months, Change from Baseline in Corticospinal Tract Myelin Water Fraction at 3 Months, Change from Baseline in Corticospinal Tract Myelin Water Fraction at 6 Months, Change from Baseline in Corticospinal Tract T1 Relaxation Time at 6 Months, Change from Baseline in Corticospinal Tract UTE Fraction at 3 Months, Change from Baseline in Corticospinal Tract UTE Fraction at 6 Months
Neurology